These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 19272616

  • 1. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K, Topakian R, Schäffer V, Aichner FT.
    J Neurol Sci; 2009 May 15; 280(1-2):120-2. PubMed ID: 19272616
    [Abstract] [Full Text] [Related]

  • 2. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.
    Rheumatology (Oxford); 2006 Nov 15; 45(11):1432-6. PubMed ID: 16632482
    [Abstract] [Full Text] [Related]

  • 3. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N, Patwa HS, Novella SP, Goldstein JM.
    Muscle Nerve; 2010 Mar 15; 41(3):375-8. PubMed ID: 19852027
    [Abstract] [Full Text] [Related]

  • 4. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy.
    Lui NL, Thumboo J, Fong KY.
    Int J Rheum Dis; 2009 Dec 15; 12(4):366-9. PubMed ID: 20374378
    [Abstract] [Full Text] [Related]

  • 5. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P.
    Arch Dermatol; 2007 Aug 15; 143(8):1033-8. PubMed ID: 17709662
    [Abstract] [Full Text] [Related]

  • 6. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP.
    J Neuroimmunol; 2008 Nov 15; 204(1-2):1-12. PubMed ID: 18783837
    [Abstract] [Full Text] [Related]

  • 7. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E.
    J Neuroimmunol; 2008 Sep 15; 201-202():90-4. PubMed ID: 18653247
    [Abstract] [Full Text] [Related]

  • 8. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.
    Ann Rheum Dis; 2008 Dec 15; 67(12):1724-31. PubMed ID: 18250115
    [Abstract] [Full Text] [Related]

  • 9. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
    El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.
    J Pediatr; 2007 Apr 15; 150(4):376-82. PubMed ID: 17382113
    [Abstract] [Full Text] [Related]

  • 10. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK, Posner MR, Spigelman Z, Ahmed AR.
    J Am Acad Dermatol; 2006 Sep 15; 55(3):449-59. PubMed ID: 16908351
    [Abstract] [Full Text] [Related]

  • 11. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr 15; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

  • 12. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP, Pascuzzi RM, Kessler K, Walsh LE, Faught PP, Ramanuja S, Pescovitz MD, Loehrer PJ.
    J Clin Neuromuscul Dis; 2009 Jun 15; 10(4):170-7. PubMed ID: 19494727
    [Abstract] [Full Text] [Related]

  • 13. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.
    Dermatology; 2007 Jun 15; 214(4):310-8. PubMed ID: 17460402
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.
    Wylam ME, Anderson PM, Kuntz NL, Rodriguez V.
    J Pediatr; 2003 Nov 15; 143(5):674-7. PubMed ID: 14615745
    [Abstract] [Full Text] [Related]

  • 15. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S, Marotte H, Miossec P.
    Muscle Nerve; 2008 Oct 15; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract] [Full Text] [Related]

  • 16. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
    Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K.
    Arch Dis Child; 2008 May 15; 93(5):401-6. PubMed ID: 18039744
    [Abstract] [Full Text] [Related]

  • 17. Role of rituximab therapy in glomerulonephritis.
    Jayne D.
    J Am Soc Nephrol; 2010 Jan 15; 21(1):14-7. PubMed ID: 18799717
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy.
    Stieglbauer K, Topakian R, Hinterberger G, Aichner FT.
    Neuromuscul Disord; 2009 Jul 15; 19(7):473-5. PubMed ID: 19467601
    [Abstract] [Full Text] [Related]

  • 19. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
    Levine TD.
    Arthritis Rheum; 2005 Feb 15; 52(2):601-7. PubMed ID: 15692974
    [Abstract] [Full Text] [Related]

  • 20. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K, Matsui N, Unai Y, Sakai W, Haji S, Udaka K, Miki H, Furukawa T, Abe M, Kaji R.
    Neuromuscul Disord; 2017 Oct 15; 27(10):918-922. PubMed ID: 28694074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.